Drugs that contain Brexpiprazole

1. List of Rexulti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888362 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618109 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US8349840 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US9839637 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 27, 2024

Market Authorisation Date: 10 July, 2015

Treatment: Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of REXULTI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in